Barcelona, Spain

Jaime Piulats

This inventor holds 3 USPTO granted patents. Top assignee: Merck Patent Gesellschaft MIT Beschrankter Haftung. Active years: 1990-1991.


% Patents Active = 100.0

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 1990-1991

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jaime Piulats: Innovator in Benzimidazolylpyridazinones

Introduction

Jaime Piulats is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of chemistry, particularly in the development of new compounds. With a total of 3 patents to his name, Piulats continues to push the boundaries of innovation.

Latest Patents

His latest patents focus on benzimidazolylpyridazinones, which are characterized by a specific formula. These compounds include variations where R¹ is a styryl or a mononuclear or binuclear heteroaryl radical containing 1-4 heteroatoms. Each heteroatom can be unsubstituted or substituted by various groups such as alkyl, alkoxy, alkylthio, halogen, OH, SH, amino, alkylamino, dialkylamino, acylamino, nitro, COOH, COOalkyl, and/or CN.

Career Highlights

Jaime Piulats is currently associated with Merck Patent Gesellschaft mit beschränkter Haftung. His work at this esteemed company has allowed him to explore and develop innovative chemical compounds that have potential applications in various industries.

Collaborations

Throughout his career, Piulats has collaborated with notable colleagues, including Rochus Jonas and Michael Klockow. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Jaime Piulats stands out as a prominent inventor in the field of chemistry, with a focus on benzimidazolylpyridazinones. His contributions and collaborations continue to shape the landscape of innovation in this area.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…